Trump's Executive Order on Drug Prices: A Look at its Effectiveness and Implications

The Trump administration has signed an executive order aiming to cut down drug prices, sending letters to major pharmaceutical companies, including AbbVie, Amgen, and Pfizer, to comply. However, experts emphasize that the administration's ability to lower costs is limited, and the effort is essentially price control. The executive order, signed in May, directs the Department of Health and Human Services to establish price targets for pharmaceutical manufacturers, with failure to comply prompting the Justice Department and the Federal Trade Commission to take enforcement action. The administration's plan, known as "most favored nations drug pricing," aims to make the prices of prescription drugs in the US equal to those in other developed countries.

Key Takeaways:

• Drug prices have increased by over 15% from January 2022 to January 2023, reaching an average of $590 per drug product.
• 46% of price increases exceeded the rate of inflation, affecting 4,200 prescription drugs included in the list.
• The executive order aims to cut down drug prices by 50 to 80 to 90% through "most favored nations drug pricing."
• Experts, including Benedic Ippolito and Michael Cannon, argue that the administration's ability to lower costs is limited and that the effort amounts to price control.
• Congressional Republicans may not support Trump's views on drug pricing, as they are generally more hesitant to introduce new laws affecting the issue.
• Reforms to Medicaid, Medicare, and the tax code could lead to reduced drug prices, but these options require Congressional action.

Statistics:

• Prescription drug prices increased by 15.1% from January 2022 to January 2023.
• The average price of a drug product reached $590 in January 2023.
• 46% of price increases exceeded the rate of inflation, affecting 4,260 prescription drugs (including data from January 2023).
• The Administration sent letters to 21 major pharmaceutical companies, including AbbVie, Amgen, and Pfizer, advocating for lower drug prices.

Sources:

• Fox News Digital (Monday): Benedic Ippolito, a senior fellow in economic policy studies at the American Enterprise Institute think tank.
• Fox News Digital (Monday): Michael Cannon, director of health policy studies at the Cato Institute think tank.
• The Department of Health and Human Services: Data on prescription drug prices for 2022 and 2023.